Successful Closure of Patent Ductus Arteriosus by Late Pharmacologic Treatment in a Small Preterm Infant

Boro Theodore, Ouedraogo Paul, Bama Aime, Seghda Arthur, Zagre Nicaise, Zabsonre Patrice, Simpore Jacques ; American Journal of Pediatrics 2019 ; 5(4) : 276-280 ; http://www.sciencepublishinggroup.com/j/ajp
doi : 10.11648/j.ajp.20190504.29 ; ISSN : 2472-0887 (Print) ; ISSN : 2472-0909 ;

Abstract :
The ductus arteriosus (DA) is a temporary communicative pathway that connects the pulmonary artery to the aorta during fœtal life. Although usually closing on its own in the initial days of postnatal life, the persistent patency of the DA is common in preterm or low birth weight babies, and can lead to life-threatening complications. Early diagnosis and pharmacologic management of patent ductus arteriosus (PDA) could prevent further need for invasive surgery or transcatheter intervention. Pharmacologic treatment for PDA closure in preterm infants is achieved by cyclooxygenase inhibitors (COXi) and paracetamol. However, their effectiveness is fully demonstrated when they are used early within the first week of postnatal life. We report here the case of a severe preterm infant of 27 weeks gestation age with extremely low birth weight (995g), who had a PDA with moderate to severe shunting closed after late administration of intravenous ibuprofen. Ibuprofen was started on postnatal day 40, and the PDA got closed after a three-day course of treatment. No complication related to the treatment was reported. The DA remained closed when the infant was seen on review for echocardiography at the age of six months. Wherever cardiac surgery and transcatheter intervention are not available nor affordable, possible effectiveness of COXi even in case of late diagnosis of PDA, offers an unexpected opportunity to cure at a very cheaper cost, one of the commonest congenital heart disease.

Keywords :
Patent Ductus Arteriosus, Preterm Infant, Ibuprofen
To cite this article



Université Joseph KI-ZERBO : Soutenance de quatre thèses de doctorat unique (...)

Appel à candidatures pour inscription en Master de Biologie Moléculaire et de (...)

Appel à candidature pour le recrutement d’experts, animateurs d’ateliers de (...)

Code d’Ethique et de Déontologie des Enseignants-chercheurs du Burkina (...)

Copyright LaBioGene 2013 - 2014